Ichinosuke Hyodo

11.3k total citations · 1 hit paper
263 papers, 6.8k citations indexed

About

Ichinosuke Hyodo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ichinosuke Hyodo has authored 263 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Oncology, 126 papers in Pulmonary and Respiratory Medicine and 67 papers in Surgery. Recurrent topics in Ichinosuke Hyodo's work include Gastric Cancer Management and Outcomes (94 papers), Colorectal Cancer Treatments and Studies (94 papers) and Cancer Treatment and Pharmacology (39 papers). Ichinosuke Hyodo is often cited by papers focused on Gastric Cancer Management and Outcomes (94 papers), Colorectal Cancer Treatments and Studies (94 papers) and Cancer Treatment and Pharmacology (39 papers). Ichinosuke Hyodo collaborates with scholars based in Japan, United States and South Korea. Ichinosuke Hyodo's co-authors include Narikazu Boku, Atsushi Ohtsu, Hirofumi Matsui, Kuniaki Shirao, Tsuyoshi Kaneko, Tomohiro Nishina, Yasuhiro Shimada, Toshikazu Moriwaki, Masahito Tanimizu and Hiroshi Saito and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Ichinosuke Hyodo

253 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

2013 351 citations Shuichi Hironaka, Hirofumi Yasui et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Ichinosuke Hyodo

Since Specialization

Citations

This map shows the geographic impact of Ichinosuke Hyodo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ichinosuke Hyodo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ichinosuke Hyodo more than expected).

Fields of papers citing papers by Ichinosuke Hyodo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ichinosuke Hyodo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ichinosuke Hyodo. The network helps show where Ichinosuke Hyodo may publish in the future.

Co-authorship network of co-authors of Ichinosuke Hyodo

This figure shows the co-authorship network connecting the top 25 collaborators of Ichinosuke Hyodo. A scholar is included among the top collaborators of Ichinosuke Hyodo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ichinosuke Hyodo. Ichinosuke Hyodo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer 2025 ·Journal of Clinical Oncology ·Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama, Masahiro Tsuda, Kenro Hirata, Naotoshi Sugimoto, Nozomu Machida, Hiroki Hara, Hidekazu Hirano, Taito Esaki, Yoshito Komatsu, Shuichi Hironaka, Yukari Kobayashi, Kazuhiro Kakimi, Yasutaka Chiba, Narikazu Boku, Ichinosuke Hyodo, (unknown)	2
2	Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN) 2023 ·Cancers ·Takeshi Kajiwara, Tomohiro Nishina, (unknown), Yoshiaki Nakamura, Manabu Shiozawa, Satoshi Yuki, Hiroya Taniguchi, Hiroki Hara, Takashi Ohta, Taito Esaki, Eiji Shinozaki, Atsuo Takashima, Yoshiyuki Yamamoto, Kentaro Yamazaki, Takayuki Yoshino, Ichinosuke Hyodo	1
3	Identification of a gene set that maintains tumorigenicity of the hepatocellular carcinoma cell line Li-7 2023 ·Human Cell ·(unknown), Kazuhiro Sudo, (unknown), (unknown), Takeshi Yamada, Takashi Hiroyama, Ryosuke Sasaki, Masami Yokota Hirai, Ichinosuke Hyodo, Kiichiro Tsuchiya, Yukio Nakamura	2
4	Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial 2022 ·Cancers ·Takao Takahashi, Kazuyuki Ishida, Yasunori Emi, Michiie Sakamoto, Johji Imura, Shinichi Aishima, Kei Muro, Hiroyuki Uetake, Eiji Oki, Yu Katayose, Kazuhiro Yoshida, Michiaki Unno, Ichinosuke Hyodo, Naohiro Tomita, Kenichi Sugihara, Yoshihiko Maehara	2
5	Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer 2021 ·Medicine ·(unknown), Teru Kumagi, Ichinosuke Hyodo, Tomoyuki Yokota, Nobuaki Azemoto, Hideki Miyata, Taira Kuroda, (unknown), Yoshinori Tanaka, (unknown), Yoshiki Imamura, (unknown), Teruki Miyake, Mitsuhito Koizumi, Yoichi Hiasa	5
6	Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G 2021 ·Cancer Medicine ·Hiroyuki Arai, Eisuke Inoue, Kensei Yamaguchi, Narikazu Boku, Hiroki Hara, Tomohiro Nishina, Masahiro Tsuda, Kohei Shitara, Katsunori Shinozaki, Shinichiro Nakamura, Ichinosuke Hyodo, Kei Muro, Mitsuru Sasako, Masanori Terashima, Takako Eguchi Nakajima	2
7	Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2) 2020 ·Supportive Care in Cancer ·Yuji Miura, Masahiko Ando, Kentaro Yamazaki, Shuichi Hironaka, Narikazu Boku, Kei Muro, Ichinosuke Hyodo	7
8	A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy 2020 ·Cancer Chemotherapy and Pharmacology ·Masahito Kotaka, Yoji Saito, Takeshi Kato, Hironaga Satake, Akitaka Makiyama, Yasushi Tsuji, Katsunori Shinozaki, Toshiyoshi Fujiwara, Tsunekazu Mizushima, Yasushi Harihara, Naoki Nagata, Naoto Kurihara, Masahiko Ando, (unknown), Takumi Sakai, (unknown), (unknown), (unknown), Ichinosuke Hyodo	16
9	Correction to: A placebo‑controlled, double‑blind, randomized study of recombinant thrombomodulin (ART‑123) to prevent oxaliplatin‑induced peripheral neuropathy 2020 ·Cancer Chemotherapy and Pharmacology ·Masahito Kotaka, Yoji Saito, Takeshi Kato, Hironaga Satake, Akitaka Makiyama, Yasushi Tsuji, Katsunori Shinozaki, Toshiyoshi Fujiwara, Tsunekazu Mizushima, Yasushi Harihara, Naoki Nagata, Naoto Kurihara, Masahiko Ando, (unknown), Takumi Sakai, (unknown), (unknown), (unknown), Ichinosuke Hyodo	2
10	A robust culture method for maintaining tumorigenic cancer stem cells in the hepatocellular carcinoma cell line Li‐7 2019 ·Cancer Science ·(unknown), Takeshi Yamada, Takashi Hiroyama, Kazuhiro Sudo, Naoyuki Hasegawa, Ichinosuke Hyodo, Yukio Nakamura	2
11	Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer 2019 ·Cancer Science ·Yasuhide Yamada, Wasaburo Koizumi, Kazuhiro Nishikawa, Masahiro Gotoh, Nozomu Fuse, Naotoshi Sugimoto, Tomohiro Nishina, Kenji Amagai, Keisho Chìn, Yasumasa Niwa, Akihito Tsuji, Hiroshi Imamura, Masahiro Tsuda, Hirofumi Yasui, Hirofumi Fujii, Kensei Yamaguchi, Hisateru Yasui, Shuichi Hironaka, Ken Shimada, Ichinosuke Hyodo	12
12	Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER) 2019 ·International Journal of Clinical Oncology ·Toshikazu Moriwaki, Yoshinori Sakai, Hiroyasu Ishida, Yoshiyuki Yamamoto, Shinji Endo, (unknown), Mikio Sato, Yukimasa Hatachi, Yoshiaki Bando, Takashi Maeba, (unknown), Mitsuo Shimada, Kenji Amagai, (unknown), Kazuma Kobayashi, Akihito Tsuji, Tomohiro Nishina, Ichinosuke Hyodo	3
13	Rebamipide attenuates nonsteroidal anti-inflammatory drugs (NSAID) induced lipid peroxidation by the manganese superoxide dismutase (MnSOD) overexpression in gastrointestinal epithelial cells. 2012 ·PubMed ·Yumiko Nagano, Hirofumi Matsui, Osamu Shimokawa, Aki Hirayama, Masato Tamura, Yukio Nakamura, Tsuyoshi Kaneko, (unknown), Hiroko P. Indo, Hideyuki J. Majima, Ichinosuke Hyodo	19
14	Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice 2008 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·Kosuke Okada, Junichi Shoda, Keiko Taguchi, Jonathan Maher, (unknown), Yoshimi Inoue, M Ohtsuki, Nobuharu Gotô, Koichi Takeda, Hirotoshi Utsunomiya, Koji Oda, Eiji Warabi, Tetsuro Ishii, (unknown), Ichinosuke Hyodo, Masayuki Yamamoto	123
15	Neoplastic transformation and induction of H+,K+-adenosine triphosphatase by N-methyl-N′-nitro-N-nitrosoguanidine in the gastric epithelial RGM-1 cell line 2007 ·In Vitro Cellular & Developmental Biology - Animal ·Osamu Shimokawa, Hirofumi Matsui, Yumiko Nagano, Tsuyoshi Kaneko, Takeshi Shibahara, Akira Nakahara, Ichinosuke Hyodo, Akinori Yanaka, Hideyuki J. Majima, Yukio Nakamura, Yasushi Matsuzaki	41
16	Daily intake of sulphoraphane-rich broccoli sprouts prevents colon tumor formation in mice treated with dextran sodium sulfate and azoxymethane via stimulating nrf2-dependent antioxidant enzymes. 2006 ·Cancer Epidemiology and Prevention Biomarkers ·Akinori Yanaka, Ichinosuke Hyodo, Masayuki Yamamoto	0
17	[Malignant lymphoma with submucosal invasion in the terminal ileum diagnosed with colonoscopy and examined by endoscopic ultrasonography]. 2004 ·PubMed ·Shoji Hirasaki, Ichinosuke Hyodo, Takeshi Kajiwara, Tomohiro Nishina, Toshikazu Masumoto	2
18	Total necrosis of hepatocellular carcinoma with a combination therapy of arterial infusion of chemotherapeutic lipiodol and transcatheter arterial embolization: report of 14 cases. 1997 ·PubMed ·(unknown), Ichinosuke Hyodo, Masahito Tanimizu, Minoru Tanada, (unknown), (unknown), (unknown), S Moriwaki	13
19	The statistical and clinical investigation of seroconversion from HBeAg to anti-HBe in type B chronic liver disease 1985 ·Kanzo ·(unknown), Gotaro Yamada, (unknown), Ichinosuke Hyodo, Shigeatsu Fujiki, Takashi Nishihara, Motowo Mizuno, Shingo Kinoyama, Yuji Sakamoto, Hideo Nagashima	4
20	Immunohistochemical study of intrahepatic distribution of lymphocyte subsets in cases with non-A, non-B chronic hepatitis. 1984 ·Kanzo ·Takashi Nishihara, Gotaro Yamada, Ichinosuke Hyodo, Yuji Sakamoto, Shingo Kinoyama, (unknown), (unknown), Motowo Mizuno, Hideo Nagashima	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact